Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study).
Axitinib
Biliary tract cancer
Chemotherapy refractory
Gemcitabine
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
11
07
2020
accepted:
27
09
2020
pubmed:
4
10
2020
medline:
22
6
2021
entrez:
3
10
2020
Statut:
ppublish
Résumé
Axitinib exhibited marginal activity against gemcitabine-refractory unselected biliary tract cancer. Pretreated soluble vascular endothelial growth factor receptor-2 may be a useful biomarker for axitinib treatment outcome. Ascites should be carefully monitored in patients receiving anti-vascular endothelial growth factor receptor therapy including axitinib in advanced biliary tract cancer. There are no clear options for second-line treatment in patients with gemcitabine (GEM)-refractory biliary tract cancer (BTC). We conducted a multicenter, single-arm, phase II trial to confirm the efficacy and safety of axitinib, a potent selective inhibitor of vascular endothelial growth factor receptor (VEGFR)-1/2/3, in patients with GEM-refractory BTC. Patients refractory or intolerant to GEM-based chemotherapy were enrolled. Axitinib was administered orally at an initial dose of 5 mg twice daily. The primary endpoint was progression-free survival (PFS), and the threshold and expected values were set at 2 and 3 months, respectively. The target sample size was 32 patients. Nineteen patients were enrolled. The trial was interrupted for a total of 13 months for the evaluation of adverse events. Thirteen patients were previously treated with ≥2 regimens. The median PFS was 2.8 months (95% confidence interval [CI]: 2.1-4.1). The median overall survival was 5.8 months (95% CI: 3.3-9.7). The response rate was 5.3% (95% CI: 0.0-15.3). Grade 3 ascites occurred in two patients. Baseline soluble VEGFR-2 levels were significantly associated with PFS. Axitinib exhibited marginal activity against GEM-refractory BTC. Ascites should be carefully monitored in axitinib-treated patients with advanced BTC.
Sections du résumé
LESSONS LEARNED
Axitinib exhibited marginal activity against gemcitabine-refractory unselected biliary tract cancer. Pretreated soluble vascular endothelial growth factor receptor-2 may be a useful biomarker for axitinib treatment outcome. Ascites should be carefully monitored in patients receiving anti-vascular endothelial growth factor receptor therapy including axitinib in advanced biliary tract cancer.
BACKGROUND
There are no clear options for second-line treatment in patients with gemcitabine (GEM)-refractory biliary tract cancer (BTC). We conducted a multicenter, single-arm, phase II trial to confirm the efficacy and safety of axitinib, a potent selective inhibitor of vascular endothelial growth factor receptor (VEGFR)-1/2/3, in patients with GEM-refractory BTC.
METHODS
Patients refractory or intolerant to GEM-based chemotherapy were enrolled. Axitinib was administered orally at an initial dose of 5 mg twice daily. The primary endpoint was progression-free survival (PFS), and the threshold and expected values were set at 2 and 3 months, respectively. The target sample size was 32 patients.
RESULTS
Nineteen patients were enrolled. The trial was interrupted for a total of 13 months for the evaluation of adverse events. Thirteen patients were previously treated with ≥2 regimens. The median PFS was 2.8 months (95% confidence interval [CI]: 2.1-4.1). The median overall survival was 5.8 months (95% CI: 3.3-9.7). The response rate was 5.3% (95% CI: 0.0-15.3). Grade 3 ascites occurred in two patients. Baseline soluble VEGFR-2 levels were significantly associated with PFS.
CONCLUSION
Axitinib exhibited marginal activity against GEM-refractory BTC. Ascites should be carefully monitored in axitinib-treated patients with advanced BTC.
Identifiants
pubmed: 33010112
doi: 10.1002/onco.13547
pmc: PMC7873316
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Deoxycytidine
0W860991D6
Axitinib
C9LVQ0YUXG
Gemcitabine
0
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
97-e201Informations de copyright
© AlphaMed Press; the data published online to support this summary are the property of the authors.
Références
Int J Cancer. 2020 Oct 15;147(8):2190-2198
pubmed: 32359091
Cancer. 2015 Sep 15;121(18):3290-7
pubmed: 26052689
Eur J Cancer. 2020 May;130:219-227
pubmed: 32234665
Cancer Chemother Pharmacol. 2009 Dec;65(1):113-20
pubmed: 19404641
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Br J Cancer. 2017 Feb 28;116(5):561-567
pubmed: 28081540
Jpn J Clin Oncol. 2014 Jun;44(6):570-8
pubmed: 24755544
Anticancer Res. 1999 May-Jun;19(3B):2257-60
pubmed: 10472340
Br J Cancer. 2018 Jan;118(2):e2
pubmed: 29315294
Lancet Gastroenterol Hepatol. 2019 Aug;4(8):611-621
pubmed: 31109808
Cancer. 2017 Jun 1;123(11):1979-1988
pubmed: 28192597
Eur J Cancer. 2012 Jan;48(2):196-201
pubmed: 22176869
Drugs R D. 2011;11(2):113-26
pubmed: 21679004
Br J Cancer. 2008 Jan 29;98(2):418-25
pubmed: 18087285
J Clin Oncol. 2011 Jun 10;29(17):2357-63
pubmed: 21519026
Cancer Chemother Pharmacol. 2013 May;71(5):1141-6
pubmed: 23525694
JAMA Oncol. 2020 Jun 1;6(6):888-894
pubmed: 32352498
Oncoimmunology. 2015 Jan 22;4(4):e998107
pubmed: 26137411
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Cancer Sci. 2018 Jan;109(1):215-224
pubmed: 29121415
Eur J Cancer. 2011 Nov;47(17):2592-602
pubmed: 21889330
Ann Oncol. 2014 Dec;25(12):2328-2338
pubmed: 24769639
Anticancer Res. 2017 Jul;37(7):3711-3715
pubmed: 28668864
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Cancer. 2019 Mar 15;125(6):902-909
pubmed: 30561756
Br J Cancer. 2010 Jan 5;102(1):68-72
pubmed: 19935794